Innovative retatrutide, a combined-action drug targeting both GLP-1 and GIP receptors, is creating considerable buzz within the weight loss community. Initial clinical research have shown significant decreases in body size and gains in health markers for patients with excess weight . Researchers believe this ground-breaking approach could mark a k